Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 80

Results For "2022"

1455 News Found

AstraZeneca likely to see substantial Evusheld uptake in Japan, says GlobalData
Drug Approval | September 13, 2022

AstraZeneca likely to see substantial Evusheld uptake in Japan, says GlobalData

Japan’s Ministry of Health, Labour and Welfare (MHLW) has recently approved AstraZeneca's long-acting antibody combination “Evusheld” for the prevention ) and treatment of COVID-19.


We will vaccinate 100% of the animals by 2025: Narendra Modi
Policy | September 13, 2022

We will vaccinate 100% of the animals by 2025: Narendra Modi

The Prime Minister addressed a major problem that is affecting the income of farmers which is the diseases of animals and emphasised that in this direction India is working towards universal vaccination of animals


Merck and Eisai present results from Phase 3 LEAP-002 Trial evaluating KEYTRUDA
Clinical Trials | September 12, 2022

Merck and Eisai present results from Phase 3 LEAP-002 Trial evaluating KEYTRUDA

Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022


Lupin Launches Generic Suprep Bowel Prep Kit in US
Drug Approval | September 10, 2022

Lupin Launches Generic Suprep Bowel Prep Kit in US

Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution (RLD Suprep Bowel Prep Kit) had estimated annual sales of US $202 mn in the US


Lynparza with Bevacizumab demonstrates survival in certain patients with first-line advanced ovarian cancer
Clinical Trials | September 10, 2022

Lynparza with Bevacizumab demonstrates survival in certain patients with first-line advanced ovarian cancer

The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients


Panacea Biotec received US FDA communication for Baddi facility
Drug Approval | September 09, 2022

Panacea Biotec received US FDA communication for Baddi facility

The OAI classification implies that the USFDA expects further corrective actions and may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved


We can create Seva Bhav by donating organs...: Dr. Mandaviya
News | September 09, 2022

We can create Seva Bhav by donating organs...: Dr. Mandaviya

Despite having rich knowledge and defined responsibility, there has been less than expected response towards organ donation from our citizens


Health Secretary addresses workshop on 'Roadmap to Strengthen Public Health Preparedness and Response Capabilities of Points of Entry (PoEs) in India'
Policy | September 08, 2022

Health Secretary addresses workshop on 'Roadmap to Strengthen Public Health Preparedness and Response Capabilities of Points of Entry (PoEs) in India'

India is an example in front of the world to contribute towards strengthening Points of Entry during a public health emergency


Cipla receives US FDA approval for Revlimid (Lenalidomide) capsules
Drug Approval | September 08, 2022

Cipla receives US FDA approval for Revlimid (Lenalidomide) capsules

Depending on the type of cancer, it can be used as monotherapy or combination as a part of first line regimen, maintenance regimen or relapsed settings


Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
interviews | September 05, 2022

Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries

We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.